scholarly journals Microscopic colitis: A literature review

2016 ◽  
Vol 62 (9) ◽  
pp. 895-900 ◽  
Author(s):  
ANA PAULA HAMER SOUSA CLARA ◽  
FLÁVIA DRAGO MAGNAGO ◽  
JULIANA NEVES FERREIRA ◽  
THAIS GAGNO GRILLO
Keyword(s):  
Scientific Evidence ◽  
Collagenous Colitis ◽  
Gastrointestinal Disorder ◽  
Normal Mucosa ◽  
Term Treatment ◽  
Diagnostic Methods ◽  
Microscopic Colitis ◽  
Older Individuals ◽  
Short Term Treatment ◽  
Pubmed Database

SUMMARY Microscopic colitis (MC) refers to chronic inflammation of the colon which is characterized by histologic changes at the level of a radiologically and endoscopically normal mucosa. It is a common cause of chronic non-bloody diarrhea that occurs primarily in older individuals; however, there are few studies in the literature with strong scientific evidence compared to other inflammatory bowel diseases (IBD), which limits the knowledge of physicians and pathologists. This article aims to review the information on MC, describing diagnostic methods and drugs available for treatment. We conducted a search of the Pubmed database and CAPES Portal using the keywords “microscopic colitis”, “collagenous colitis”, “lymphocytic colitis”, and “review” for selection of articles published between 1996 and 2015 related to the topic. Based on the studies discussed in this review, we conclude that MC is a relatively new gastrointestinal disorder, most studies are incipient particularly with respect to pathophysiology and immunology, and budesonide is the best documented short-term treatment. However, further studies are needed to elucidate the best strategy for treatment in the long term.

scholarly journals P510 European multicenter trial of budesonide and mesalazine for short-term treatment of active collagenous colitis (BUC60/COC)

2013 ◽  
Vol 7 ◽  
pp. S214 ◽  
Author(s):  
S. Miehlke ◽  
A. Madisch ◽  
L. Kupcinskas ◽  
D. Petrauskas ◽  
G. Heptner ◽  
...  
Keyword(s):  
Collagenous Colitis ◽  
Multicenter Trial ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

Placebo controlled studies in acute schizophrenia – an issue of concern

1994 ◽  
Vol 9 (4) ◽  
pp. 165-173 ◽  
Author(s):  
A Delini-Stula ◽  
D Berdah-Tordjman
Keyword(s):  
Scientific Evidence ◽  
A Priori ◽  
Term Treatment ◽  
Drop Out ◽  
Assessment Instruments ◽  
Duration Of Treatment ◽  
Short Term Treatment ◽  
Improvement Rate ◽  
Acute Schizophrenia ◽  
Reported Data

SummaryPlacebo controlled studies in patients suffering from exacerbation eg acute productive episode of schizophrenia and performed in the period between 1963-1993 are reviewed and analysed with respect to study designs; size of studies; improvement rate under placebo and drop-outs due to inefficacy under placebo. The aim of the analysis was to find out if the reported data permit some realistic estimates for a priori assumptions needed for proper planning of such studies, particularly in view of the numerous ethical and other difficulties which their performance encounters in the practice. Literature research revealed a rather limited number of rigorous, placebo-controlled, monotherapy studies (without intermittent or concomitant additional neuroleptics) in acute schizophrenia. Across comparison of findings from these studies was difficult due to differences in duration of treatment, assessment instruments and criteria of efficacy which illustrated a lack of methodological standards for studies in this indication. The improvement rate under placebo, if measured by Clinical Global Assessment (CGI) appeared, however, not to exceed 25%, whereas BPRS score reduction as efficacy criterion mostly provided higher response rates (up to 40%). Of interest however, is the finding that the response rate to conventional neuroleptics at the end of 4-6 weeks of treatment in some studies hardly exceeded 40%. The most sensitive measure of placebo effect seemed to be the drop-out rate due to inefficacy (up to 100%) and it is suggested to consider this measure and the survival analysis approach in designing future studies. The review demonstrated many unresolved methodological problems in testing antipsychotic drugs in acute schizophrenia and, particularly, the need of scientific evidence of validity and sensitivity of measures of antipsychotic efficacy. The findings reported up to now do not offer cues for rational estimates of the effect size differences between placebo and active drugs after short-term treatment in acute schizophrenia.

scholarly journals Budesonide Is More Effective Than Mesalamine or Placebo in Short-term Treatment of Collagenous Colitis

2014 ◽  
Vol 146 (5) ◽  
pp. 1222-1230.e2 ◽  
Author(s):  
Stephan Miehlke ◽  
Ahmed Madisch ◽  
Limas Kupcinskas ◽  
Dalius Petrauskas ◽  
Günter Böhm ◽  
...  
Keyword(s):  
Collagenous Colitis ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

Anticancer Effects & Comparative Study of Thymoquinone, Cordyceps, Spirulina, Ganoderma Lucidium, Poria Cocos, and Lion’s Mane on Human Nasal Cancer Cells (RPMI-2650)

2020 ◽  
pp. 62-78
Author(s):  
سعيد مزعل موازي ◽  
يحيى فائق حسين ◽  
عبد المنعم دولاني ◽  
سيف يوسف عبدالله السويدي
Keyword(s):  
Term Treatment ◽  
Epithelial Cell Line ◽  
Anticancer Effect ◽  
Short Term Treatment ◽  
Poria Cocos ◽  
Nasal Cancer ◽  
Antineoplastic Effect ◽  
Long Term Treatment ◽  
High Concentrations

Recently, many studies have been conducted to discover or improve cancers treatment. The current study aims to investigate the anticancer effect of thymoquinone, cordyceps, spirulina, ganoderma lucidium, poria cocos, and lion’s mane in four different concentrations 4, 8, 16, and 32 ug (equivalent to 1 mg/mL) in two different time treatments (48 and 96 hours) on human nasal epithelial cell line RPMI 2650. By using cell culture cytotoxicity techniques and assay, the highest anticancer effect on RPMI 2650 was obtained by thymoquinone. The lowest anticancer effect was demonstrated by poria cocos and cordyceps. However, these two medications showed higher anticancer effect when given in short-term treatment (48 hours) compared to long-term treatment (96 hours). Ganoderma lucidium and spirulina showed better impact than poria cocos, cordyceps, and lion’s mane in term of cells cytotoxicity. Mild to moderate antineoplastic effect was seen by utilizing lion’s mane treatment compared other drugs. Therefore, adopting a long-term treatment of high concentrations and doses of thymoquinone, cordyceps, spirulina, ganoderma lucidium, poria cocos, and lion’s mane can be more effective in the treatment of nasal cancer. In conclusion, these drugs were found to be a promising cancer remedy; therefore, they can be utilized as alternative treatment for nasal cancer or any other type of cancer therapy.

scholarly journals The plant secondary compound swainsonine reshapes gut microbiota in plateau pikas (Ochotona curzoniae)

2021 ◽  
Author(s):  
Shien Ren ◽  
Chao Fan ◽  
Liangzhi Zhang ◽  
Xianjiang Tang ◽  
Haibo Fu ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Artificial Diet ◽  
Alpha Diversity ◽  
Term Treatment ◽  
Short Term Treatment ◽  
Ochotona Curzoniae ◽  
Rdna Sequencing ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Herbivorous Mammals

Abstract Plants produce various plant secondary compounds (PSCs) to deter the foraging of herbivorous mammals. However, little is known about whether PSCs can reshape gut microbiota and promote gut homeostasis of hosts. Using 16S rDNA sequencing to investigate the effects of PSCs on the gut microbiota of small herbivorous mammals, we studied plateau pikas (Ochotona curzoniae) fed diets containing swainsonine (SW) extracted from Oxytropis ochrocephala. Our results showed that both long- and short-term treatment of a single artificial diet in the laboratory significantly reduced alpha diversity and significantly affected beta diversity, core bacteria abundance, and bacterial functions in pikas. After SW was added to the artificial diet, the alpha diversity significantly increased in the long-term treatment, and core bacteria (e.g., Akkermansiaceae) with altered relative abundances in the two treatments showed no significant difference compared with pikas in the wild. The complexity of the co-occurrence network structure was reduced in the artificial diet, but it increased after SW was added in both treatments. Further, the abundances of bacteria related to altered alanine, aspartate, and glutamate metabolism in the artificial diet were restored in response to SW. SW further decreased the concentration of short-chain fatty acids (SCFAs) in both treatments. Our results suggest that PSCs play a key role in regulating gut microbiota community and intestinal homeostasis, thereby maintaining host health. Key points • Swainsonine improves the intestinal bacterial diversity of plateau pikas. • Swainsonine promotes the recovery of core bacterial abundances in the gut of plateau pikas. • Swainsonine promotes the restoration of intestinal bacterial functions of plateau pikas.

scholarly journals KIDNEY INJURY MOLECULE-1 AS AN EARLY AMIKACIN-INDUCED NEPHROTOXICITY MARKER IN PATIENTS WITH SEPSIS HOSPITALIZED IN THE INTENSIVE CARE UNIT

2019 ◽  
pp. 277-279
Author(s):  
TRISNI UNTARI DEWI ◽  
INSTIATY . ◽  
RUDIANTO SEDONO ◽  
GESTINA ALISKA ◽  
MUHAMMAD KHIFZHON AZWAR ◽  
...  
Keyword(s):  
Intensive Care ◽  
Kidney Injury ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Safe Level ◽  
Study Results ◽  
Early Biomarker ◽  
Kidney Injury Molecule 1 ◽  
Trough Plasma

Objective: This study sought to determine the correlation between trough plasma amikacin concentrations and urinary normalized kidney injurymolecule-1 (KIM-1) concentrations as an early biomarker of nephrotoxicity in patients with sepsis who are hospitalized in an intensive care unit.Methods: In this pilot study, 12 patients with sepsis were treated with amikacin 1000 mg/day between May 2015 and September 2015. The correlationbetween trough plasma amikacin concentrations measured after the third dose and the elevation of urinary normalized KIM-1 concentrations afterthe third amikacin dose relative to the first/second dose was evaluated.Results: In total, three patients had trough plasma amikacin concentrations exceeding the safe level (>10 μg/ml). Furthermore, eight patientsdisplayed higher normalized KIM-1 concentrations after third dose than after the first/second dose; however, there was no correlation betweentrough amikacin concentrations and the elevation of urinary normalized KIM-1 concentrations (r=0.3, p=0.3).Conclusion: The study results illustrated that short-term treatment with an amikacin dose of 1000 mg/day was generally safe in patients with sepsis.

Sign in / Sign up

Export Citation Format

Share Document